Trials / Completed
CompletedNCT03322462
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 155 (actual)
- Sponsor
- Avid Radiopharmaceuticals · Industry
- Sex
- All
- Age
- 60 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This protocol is designed to serve as a pre-screening study for subjects who are potentially eligible for Alzheimer's Disease (AD) therapeutic trials that require tau imaging for inclusion by means of a flortaucipir F18 Positron Emission Tomography (PET) scan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Flortaucipir F18 | 370 megabecquerel (MBq) IV single-dose |
| PROCEDURE | Brain PET Scan | positron emission tomography (PET) scan of the brain |
Timeline
- Start date
- 2017-11-21
- Primary completion
- 2018-08-31
- Completion
- 2018-08-31
- First posted
- 2017-10-26
- Last updated
- 2020-08-24
- Results posted
- 2020-08-24
Locations
10 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03322462. Inclusion in this directory is not an endorsement.